vs

Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $97.3M, roughly 1.3× Riley Exploration Permian, Inc.). On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -5.3%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -1.2%).

Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

NATR vs REPX — Head-to-Head

Bigger by revenue
NATR
NATR
1.3× larger
NATR
$123.8M
$97.3M
REPX
Growing faster (revenue YoY)
NATR
NATR
+10.0% gap
NATR
4.7%
-5.3%
REPX
Faster 2-yr revenue CAGR
NATR
NATR
Annualised
NATR
5.6%
-1.2%
REPX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NATR
NATR
REPX
REPX
Revenue
$123.8M
$97.3M
Net Profit
$4.1M
Gross Margin
72.5%
Operating Margin
4.3%
26.9%
Net Margin
3.3%
Revenue YoY
4.7%
-5.3%
Net Profit YoY
1379.4%
EPS (diluted)
$0.23
$4.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NATR
NATR
REPX
REPX
Q4 25
$123.8M
$97.3M
Q3 25
$128.3M
$106.9M
Q2 25
$114.8M
$85.4M
Q1 25
$113.2M
$102.5M
Q4 24
$118.2M
$102.7M
Q3 24
$114.6M
$102.3M
Q2 24
$110.6M
$105.4M
Q1 24
$111.0M
$99.7M
Net Profit
NATR
NATR
REPX
REPX
Q4 25
$4.1M
Q3 25
$5.3M
$16.3M
Q2 25
$5.3M
$30.5M
Q1 25
$4.7M
$28.6M
Q4 24
$-321.0K
Q3 24
$4.3M
$25.7M
Q2 24
$1.3M
$33.5M
Q1 24
$2.3M
$18.8M
Gross Margin
NATR
NATR
REPX
REPX
Q4 25
72.5%
Q3 25
73.3%
Q2 25
71.7%
Q1 25
72.1%
Q4 24
72.0%
Q3 24
71.3%
Q2 24
71.4%
Q1 24
71.2%
Operating Margin
NATR
NATR
REPX
REPX
Q4 25
4.3%
26.9%
Q3 25
7.0%
27.0%
Q2 25
3.7%
33.7%
Q1 25
5.4%
48.3%
Q4 24
3.8%
31.2%
Q3 24
4.6%
17.1%
Q2 24
5.1%
50.9%
Q1 24
4.2%
50.7%
Net Margin
NATR
NATR
REPX
REPX
Q4 25
3.3%
Q3 25
4.2%
15.3%
Q2 25
4.6%
35.7%
Q1 25
4.2%
27.9%
Q4 24
-0.3%
Q3 24
3.8%
25.1%
Q2 24
1.2%
31.8%
Q1 24
2.1%
18.8%
EPS (diluted)
NATR
NATR
REPX
REPX
Q4 25
$0.23
$4.02
Q3 25
$0.30
$0.77
Q2 25
$0.28
$1.44
Q1 25
$0.25
$1.36
Q4 24
$-0.02
$0.52
Q3 24
$0.23
$1.21
Q2 24
$0.07
$1.59
Q1 24
$0.12
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NATR
NATR
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$93.9M
Total DebtLower is stronger
$247.9M
Stockholders' EquityBook value
$161.6M
$634.2M
Total Assets
$261.1M
$1.2B
Debt / EquityLower = less leverage
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NATR
NATR
REPX
REPX
Q4 25
$93.9M
Q3 25
$95.6M
Q2 25
$81.3M
Q1 25
$86.5M
Q4 24
$84.7M
Q3 24
$78.7M
Q2 24
$68.7M
Q1 24
$77.8M
Total Debt
NATR
NATR
REPX
REPX
Q4 25
$247.9M
Q3 25
$367.0M
Q2 25
$275.2M
Q1 25
$249.3M
Q4 24
$269.5M
Q3 24
$288.6M
Q2 24
$322.7M
Q1 24
$2.1M
$341.8M
Stockholders' Equity
NATR
NATR
REPX
REPX
Q4 25
$161.6M
$634.2M
Q3 25
$166.7M
$566.5M
Q2 25
$163.7M
$556.9M
Q1 25
$167.1M
$532.4M
Q4 24
$161.0M
$510.6M
Q3 24
$162.6M
$507.4M
Q2 24
$156.4M
$489.0M
Q1 24
$159.7M
$434.6M
Total Assets
NATR
NATR
REPX
REPX
Q4 25
$261.1M
$1.2B
Q3 25
$264.8M
$1.2B
Q2 25
$254.9M
$1.0B
Q1 25
$252.7M
$994.9M
Q4 24
$240.9M
$993.5M
Q3 24
$245.3M
$997.9M
Q2 24
$235.8M
$1.0B
Q1 24
$247.3M
$956.4M
Debt / Equity
NATR
NATR
REPX
REPX
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.57×
Q2 24
0.66×
Q1 24
0.01×
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NATR
NATR
REPX
REPX
Operating Cash FlowLast quarter
$9.9M
$64.9M
Free Cash FlowOCF − Capex
$7.6M
FCF MarginFCF / Revenue
6.1%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
2.41×
TTM Free Cash FlowTrailing 4 quarters
$28.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NATR
NATR
REPX
REPX
Q4 25
$9.9M
$64.9M
Q3 25
$18.5M
$63.6M
Q2 25
$4.3M
$33.6M
Q1 25
$2.6M
$50.4M
Q4 24
$12.2M
$66.4M
Q3 24
$9.6M
$72.1M
Q2 24
$1.3M
$51.6M
Q1 24
$2.2M
$56.1M
Free Cash Flow
NATR
NATR
REPX
REPX
Q4 25
$7.6M
Q3 25
$16.8M
Q2 25
$3.0M
Q1 25
$1.5M
Q4 24
$10.0M
Q3 24
$7.9M
Q2 24
$-2.0M
Q1 24
$-1.5M
FCF Margin
NATR
NATR
REPX
REPX
Q4 25
6.1%
Q3 25
13.1%
Q2 25
2.6%
Q1 25
1.3%
Q4 24
8.5%
Q3 24
6.9%
Q2 24
-1.9%
Q1 24
-1.4%
Capex Intensity
NATR
NATR
REPX
REPX
Q4 25
1.9%
Q3 25
1.3%
Q2 25
1.2%
Q1 25
1.0%
Q4 24
1.9%
Q3 24
1.5%
Q2 24
3.0%
Q1 24
3.3%
Cash Conversion
NATR
NATR
REPX
REPX
Q4 25
2.41×
Q3 25
3.46×
3.90×
Q2 25
0.81×
1.10×
Q1 25
0.55×
1.76×
Q4 24
Q3 24
2.21×
2.81×
Q2 24
0.97×
1.54×
Q1 24
0.94×
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NATR
NATR

Other$68.1M55%
General Health Products$20.2M16%
Digestive Products$13.8M11%
Cardiovascular Products$12.1M10%
Personal Care Products$4.4M4%
Immunity Products$3.1M3%
Weight Management Products$2.1M2%

REPX
REPX

Segment breakdown not available.

Related Comparisons